Free Access
Med Sci (Paris)
Volume 35, Novembre 2019
Les Cahiers de Myologie
Page(s) 11 - 14
Section Actualités thérapeutiques
Published online 20 December 2019
  1. Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 2016; 388: 3017–26. [CrossRef] [PubMed] [Google Scholar]
  2. Chiriboga CA, Swoboda KJ, Darras BT, et al. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology Mar 2016; 86: 890–7. [Google Scholar]
  3. Darras BT. Spinal muscular atrophies. Pediatr Clin North Am 2015; 62: 743–66. [CrossRef] [PubMed] [Google Scholar]
  4. Kolb SJ, Coffey CS, Yankey JW, et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol 2017; 82: 883–91. [CrossRef] [PubMed] [Google Scholar]
  5. Verhaart IEC, Robertson A, Wilson IJ, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy : a literature review. Orphanet J Rare Dis 2017; 12: 124. [CrossRef] [PubMed] [Google Scholar]
  6. Lefebvre S, Bürglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995; 80: 155–65. [CrossRef] [PubMed] [Google Scholar]
  7. Urtizberea JA, Daidj F. Réseau Filnemus. Med Sci (Paris) 2018; 34(hs2): 32–4. [Google Scholar]
  8. Kariya S, Obis T, Garone C, et al. Requirement of enhanced survival motoneuron protein imposed during neuromuscular junction maturation. J Clin Invest 2012; 124: 785–800. [Google Scholar]
  9. Bernal S, Alías L, Barceló MJ, et al. The c.859G>C variant in the SMN2 gene is associated with types II and III SMA and originates from a common ancestor. Med Genet 2010; 47: 640–2. [Google Scholar]
  10. Vezain M, Saugier-Veber P, Goina E, et al. A rare SMN2 variant in a previously unrecognized composite splicing regulatory element induces exon 7 inclusion and reduces the clinical severity of spinal muscular atrophy. Hum Mutat 2010; 31: E1110–25. [CrossRef] [PubMed] [Google Scholar]
  11. Wu X, Wang SH, Sun J, et al. A-44G transition in SMN2 intron 6 protects patients with spinal muscular atrophy. Hum Mol Genet 2017; 26: 2768–80. [CrossRef] [PubMed] [Google Scholar]
  12. Glascock J, Sampson J, Haidet-Phillips A, et al. Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening. J Neuromuscul Dis 2018; 5: 145–58. [CrossRef] [PubMed] [Google Scholar]
  13. Pane M, Coratti G, Sansone VA, et al. Nusinersen in type 1 spinal muscular atrophy: twelve-month real-world data. Ann Neurol 2019; 86(4): 43–51. [Google Scholar]
  14. Pechmann A, Langer T, Schorling D, et al. Evaluation of children with SMA type 1 under treatment with Nusinersen within the expanded access program in Germany. J Neuromuscul Dis 2018; 5: 135–43. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.